These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38743352)

  • 1. Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment.
    Tannu M; Hess CN; Gutierrez JA; Lopes R; Swaminathan RV; Altin SE; Rao SV
    Curr Cardiol Rep; 2024 Jun; 26(6):505-520. PubMed ID: 38743352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
    Gutierrez JA; Scirica BM; Bonaca MP; Steg PG; Mosenzon O; Hirshberg B; Im K; Raz I; Braunwald E; Bhatt DL
    Am J Cardiol; 2019 Jan; 123(1):145-152. PubMed ID: 30366601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
    Jukema JW; Szarek M; Zijlstra LE; de Silva HA; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Karpov Y; Moryusef A; Pordy R; Prieto JC; Roe MT; White HD; Zeiher AM; Schwartz GG; Steg PG;
    J Am Coll Cardiol; 2019 Sep; 74(9):1167-1176. PubMed ID: 30898609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome.
    Yakubov S
    Curr Med Res Opin; 2009 Nov; 25(11):2631-41. PubMed ID: 19769467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
    Bonaca MP; Gutierrez JA; Cannon C; Giugliano R; Blazing M; Park JG; White J; Tershakovec A; Braunwald E
    Lancet Diabetes Endocrinol; 2018 Dec; 6(12):934-943. PubMed ID: 30396865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Polyvascular Involvement in Patients With Peripheral Artery Disease: A Mendelian Randomization Study.
    Dikilitas O; Satterfield BA; Kullo IJ
    J Am Heart Assoc; 2020 Dec; 9(24):e017740. PubMed ID: 33287626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial.
    Gutierrez JA; Mulder H; Jones WS; Rockhold FW; Baumgartner I; Berger JS; Blomster JI; Fowkes FGR; Held P; Katona BG; Mahaffey KW; Norgren L; Hiatt WR; Patel MR
    JAMA Netw Open; 2018 Nov; 1(7):e185239. PubMed ID: 30646395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study.
    Chunawala ZS; Qamar A; Arora S; Pandey A; Fudim M; Vaduganathan M; Bhatt DL; Mentz RJ; Caughey MC
    J Card Fail; 2022 Aug; 28(8):1267-1277. PubMed ID: 35045321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyvascular Disease: Reappraisal of the Current Clinical Landscape.
    Gutierrez JA; Aday AW; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e007385. PubMed ID: 31833412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Medical Management of Peripheral Artery Disease.
    Bonaca MP; Hamburg NM; Creager MA
    Circ Res; 2021 Jun; 128(12):1868-1884. PubMed ID: 34110910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction.
    Subherwal S; Bhatt DL; Li S; Wang TY; Thomas L; Alexander KP; Patel MR; Ohman EM; Gibler WB; Peterson ED; Roe MT
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):541-9. PubMed ID: 22715460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
    Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carotid total plaque area as an independent predictor of short-term subclinical polyvascular atherosclerosis progression and major adverse cardiac and cerebrovascular events.
    Genkel V; Kuznetsova A; Lebedev E; Salashenko A; Savochkina A; Nikushkina K; Pykhova L; Sumerkina V; Shaposhnik I
    Ther Adv Cardiovasc Dis; 2023; 17():17539447231194861. PubMed ID: 37655749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender.
    Mattina A; Giammanco A; Giral P; Rosenbaum D; Carrié A; Cluzel P; Redheuil A; Bittar R; Béliard S; Noto D; Quartarone A; Averna M; Bruckert É; Gallo A
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1068-1076. PubMed ID: 31378630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymptomatic polyvascular disease and the risks of cardiovascular events and all-cause death.
    Zhang Q; Wang A; Zhang S; Li N; Chen S; Zhang Y; Zhou Y; Wu S; Zhao X
    Atherosclerosis; 2017 Jul; 262():1-7. PubMed ID: 28463782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial.
    Samsky MD; Mentz RJ; Stebbins A; Lokhnygina Y; Aday AW; Pagidipati NJ; Jones WS; Katona BG; Patel MR; Holman RR; Hernandez AF; Gutierrez JA
    Atherosclerosis; 2021 Dec; 338():1-6. PubMed ID: 34741929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.
    Weissler EH; Jones WS; Desormais I; Debus S; Mazzolai L; Espinola-Klein C; Nikol S; Nehler M; Sillesen H; Aboyans V; Patel MR
    Atherosclerosis; 2020 Dec; 315():10-17. PubMed ID: 33190107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of polyvascular disease in patients with carotid artery disease and peripheral artery disease.
    Vlajinac HD; Marinković JM; Maksimović MZ; Radak DJ; Arsić RB; Jorga JB
    Kardiol Pol; 2019 Oct; 77(10):926-934. PubMed ID: 31456586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of arterial hypertension and type 2 diabetes mellitus with type of polyvascular atherosclerotic disease.
    Dilic M; Dzubur A; Kusljugic Z; Balic S; Pepic E
    Med Arh; 2010; 64(5):264-8. PubMed ID: 21287949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.